Skip to main content
Nanalysis Scientific logo

Nanalysis Scientific — Investor Relations & Filings

Ticker · NSCI ISIN · CA63000Y1034 LEI · 529900FGAUUTMJRG1255 TSXV Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2022-02-17 Earnings Release
Country CA Canada
Listing TSXV NSCI

About Nanalysis Scientific

https://www.nanalysis.com/

Nanalysis Scientific Corp. is a global developer and manufacturer of compact Magnetic Resonance (MR) technologies, primarily focusing on benchtop Nuclear Magnetic Resonance (NMR) spectrometers and analyzers. The company's proprietary instruments, such as the Nanalysis-60 and Nanalysis-100 platforms, offer accessible, affordable, and automatable high-performance alternatives to traditional high-field NMR systems. This technology democratizes NMR spectroscopy for use in laboratory and industrial settings, including applications in quality assurance/quality control (QA/QC), process analytical technology (PAT), synthetic chemistry, pharmaceuticals, polymers, and academic teaching globally.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a corporate update from Nanalysis Scientific Corp. dated February 17, 2022. It provides unaudited financial highlights for the twelve months ended December 31, 2021, discusses recent acquisitions and financing activities, and outlines the company's outlook. It also announces a conference call to discuss these results. The document includes preliminary financial data but does not contain full audited financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also includes information about recent capital raising and acquisitions, which are significant corporate updates. The presence of a conference call announcement and detailed discussion of financial and operational highlights aligns with the characteristics of an Earnings Release (ER). The document is over 10,000 characters, so it is not a mere announcement of a report publication (RPA). It is not a call transcript (CT) since it is a pre-call announcement, not a transcript. Therefore, the best classification is Earnings Release (ER).
2022-02-17 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change related to the closing of a public offering and private placement of common shares by Nanalysis Scientific Corp. It includes specifics about the number of shares issued, prices, gross proceeds, and intended use of proceeds. The document is a regulatory filing reporting a material change event, specifically a financing transaction. It is not a full financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The content aligns with a Capital/Financing Update as it provides detailed information about fundraising activities and capital structure changes. The document length is over 6,000 characters, so it is not a mere announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-02-15 English
Decision Document (Final).pdf
Regulatory Filings Classification · 85% confidence The document is a press release from Rockhaven Resources Ltd. announcing assay results from their 2021 exploration drilling program at the Klaza Gold-Silver Project. It contains detailed drill hole assay data, mineral resource estimates, and technical information about the exploration program. There is no indication that this is a formal financial report such as an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing, audit report, or management change announcement. The content focuses on exploration results and mineral resource updates, which are typical for mining exploration news releases. Given the detailed assay results and technical data, this document is best classified as a Regulatory Filings (RNS) type, as it is a general regulatory announcement and does not fit into other specific categories like financial reports or governance disclosures. The document length (11,715 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2022-02-07 English
Decision Document (Final).pdf
Regulatory Filings Classification · 95% confidence The document is a receipt from the Alberta Securities Commission and other Canadian provincial securities regulators for a Short Form Prospectus filed by Nanalysis Scientific Corp. It references regulatory filings and prospectus receipt acknowledgments, which are typical of regulatory compliance documents rather than financial reports or announcements of financial results. The document is short (1007 characters) and serves as an official acknowledgment of filing rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2022-02-07 English
Consent letter of underwriters' legal counsel.PDF
Regulatory Filings Classification · 95% confidence The document is a letter from Dickinson Wright LLP addressed to multiple Canadian securities commissions, providing consent related to a final short form prospectus of Nanalysis Scientific Corp. It confirms the firm's consent to references in the prospectus and states compliance with a regulatory requirement. The document is short (2030 characters) and does not contain financial statements or substantive financial data. It is essentially a regulatory compliance letter related to a prospectus, not the prospectus itself or a financial report. Therefore, it fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories.
2022-02-07 English
Final short form prospectus – English.PDF
Capital/Financing Update Classification · 100% confidence The document is a short form prospectus for a new issue of common shares by Nanalysis Scientific Corp. It details the offering size, price, agents involved, fees, over-allotment options, and legal disclaimers. The text includes terms like 'short form prospectus', 'offering', 'common shares', 'agents', 'over-allotment option', and 'plan of distribution', which are typical for capital raising documents. There is no financial statement data or earnings information, nor is it a report or announcement of voting results or management changes. The document is clearly related to a financing activity, specifically a public offering of securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-02-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.